Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025)

Dianthus Therapeutics has reported Free Cash Flow over the past 8 years, most recently at -$30.6 million for Q3 2025.

  • Quarterly results put Free Cash Flow at -$30.6 million for Q3 2025, down 43.53% from a year ago — trailing twelve months through Sep 2025 was -$109.6 million (down 74.92% YoY), and the annual figure for FY2024 was -$78.3 million, down 111.75%.
  • Free Cash Flow for Q3 2025 was -$30.6 million at Dianthus Therapeutics, down from -$23.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for DNTH hit a ceiling of $16.4 million in Q3 2022 and a floor of -$30.6 million in Q3 2025.
  • Median Free Cash Flow over the past 4 years was -$15.0 million (2024), compared with a mean of -$15.1 million.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 72.02% in 2023 and later tumbled 206.08% in 2024.
  • Dianthus Therapeutics' Free Cash Flow stood at -$8.9 million in 2022, then tumbled by 33.6% to -$11.9 million in 2023, then plummeted by 131.58% to -$27.5 million in 2024, then decreased by 11.23% to -$30.6 million in 2025.
  • The last three reported values for Free Cash Flow were -$30.6 million (Q3 2025), -$23.9 million (Q2 2025), and -$27.7 million (Q1 2025) per Business Quant data.